COMP <GO>
ROIV vs ABBV // NET PROFIT MARGIN
Roivant Sciences Ltd. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ROIV 3
— ABBV 11
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
net-margins
-60.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 29.00% | -43.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 3.47% | -6.27 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 8.60% | -73.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | ROIV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 72.8 | -18.49 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 113.1x | -85.10 | ROIV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $513.86B | -$486.76B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | ABBV REV | ROIV GROSS % | ABBV GROSS % | ROIV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $61.16B | 44.0% | 70.2% | -$758.6M | $17.82B |
| FY 2024 | $29.1M | $56.33B | 44.0% | 70.0% | -$844.0M | $17.83B |
| FY 2023 | $32.7M | $54.32B | 44.0% | 44.0% | -$766.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
ABBV // BETA 1.15